List view / Grid view
St. Jude Children’s Research Hospital, in collaboration with ESR Limited, discovered that specific immune cells present in individuals months before a flu infection can better predict symptom development compared to current antibody-based methods.
Researchers provide new insights into viral evolution and have significant implications for understanding and predicting the behaviour of influenza and other mutating diseases.
Australian researchers have tested a new nasal vaccine in mice, with the potential enhance protection against COVID-19.
H84T-BanLec has viral-blocking abilities by binding to polysaccharides that are present on the surface of the viruses.
Dr Christopher Locher, Versatope Therapeutics, explains why bacterial extracellular vesicles are ideally suited for recombinant vaccines because target antigens can be expressed as fusion proteins and targeted to the lumen, membrane or surface of the vesicles. These nano-size vesicles represent a potentially safe and simple subunit vaccine delivery platform that…
Janssen's monoclonal antibody CR9114, for the potential treatment of influenza, has been exclusively licensed by Leyden Labs for development and commercialisation.
Researchers have found a small subset of antibodies that target a site at the base of the influenza virus hemagglutinin protein.
The new nanoparticle adjuvant improved antibody production following vaccination against HIV, diphtheria and influenza in mouse models.
Antibodies produced by B cells against the H1N1 influenza virus can also neutralise other strains, which could be used to developed vaccines.
Using nanoparticle liposomes, researchers have developed an experimental flu vaccine that has shown success in pre-clinical studies.
An airway-on-a-chip has been used to show that amodiaquine inhibits SARS-CoV-2 infection, making it a potential COVID-19 therapeutic.
Recent years have seen an increase in the development of biomaterial and nanoparticle-based vaccine formulations. Sushma Kumari, Sonal Asthana and Kaushik Chatterjee from the Department of Materials Engineering at the Indian Institute of Science discuss why these materials have such high potential in the fight against infectious diseases.
A new vaccine formulated with nanoparticles protected animal models from a variety of seasonal and pandemic influenza strains.
The natural language processing model trained using viral protein sequence data was able to predict promising targets for vaccines against HIV, influenza and coronaviruses.
A team has found immune cells in the lungs after infection from the flu, which protected mice against reinfection from a different strain.
